Innovative Diagnostic Technology ADOR Diagnostics specializes in multiplex molecular biology diagnostics through its NATlab system, enabling rapid and automated detection of multiple infectious disease targets within 30 to 60 minutes. This positions the company well to serve laboratories seeking high-throughput, accurate, and cost-effective diagnostic solutions.

Recent Capital Infusions With recent investments totaling 7.5 million USD and previous Series A funding of 14.5 million USD, ADOR Diagnostics demonstrates strong financial backing and investor confidence, indicating an active growth trajectory and increasing capacity to expand sales and distribution channels.

Growing Market Presence As an associate of BATM and with high-profile hires like CEO Eran Zahavy, ADOR is strategically positioned to leverage industry networks and expand its market footprint in the rapid diagnostics segment, creating sales opportunities across healthcare providers and diagnostic laboratories globally.

Targeted Customer Segments The company’s automated, sample-to-answer platforms appeal to laboratories aiming to improve diagnostic speed and accuracy, especially in infectious disease testing, providing an open opportunity for partnerships with hospital labs, public health agencies, and private diagnostic service providers.

Competitive Pricing Potential With a lean team of 2-10 employees and a revenue range of one to ten million USD, ADOR offers scalable and cost-effective diagnostics solutions, making it attractive to smaller and mid-sized labs seeking to upgrade their testing capabilities without significant infrastructure investments.